CML Alliance | Guidelines & Recommendations For Monitoring Chronic Myeloid Leukemia
CML Alliance
For Healthcare Professionals Outside the US  
 
Send to a friend Print this page Change Text Size  

About CML Alliance
Treating CML
Targeted Therapies and CML
Monitoring Treatment & Response
Monitoring Molecular Response
PCR Testing: Setting the Standards
Guidelines & Recommendations
CML Resources
CML Events
CML Clinical Trials
Novartis' Commitment to the Global CML Community
CML Alliance Patient Initiative
  Access educational resources for your patients to help them better understand and manage their CML.
Learn more >

CML Targeted Therapies
  Since its development, Glivec® has been a cornerstone of therapy for CML patients.
Learn more >
 

Guidelines and Recommendations for Monitoring CML




Evidence obtained in clinical trials and post-approval setting with CML targeted therapy has prompted experts to formulate consensus recommendations for response assessment and treatment of patients with Ph+ CML.1,2

European LeukemiaNet (ELN)


The European LeukemiaNet recommendations for monitoring CML propose a schedule of response expectations at various time points of targeted therapy for Ph+ CML, including continued molecular monitoring during CML targeted therapy. A rise in Bcr-Abl transcript levels detected during targeted therapy for Ph+ CML is a warning sign and should trigger a subsequent, more stringent, RQ-PCR analysis.2

Learn more >

To download the ELN panel’s recommendations for CML, click here. (Subscription to Blood required for free access to full text.)

National Comprehensive Cancer Network (NCCN)


Current guidelines published by the National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 20 leading cancer centers in the US, detail proposed indications for cytogenetics and PCR for Bcr-Abl mRNA, and indications for Abl kinase domain mutation analysis.

To download the NCCN’s clinical practice guidelines for CML, click here.

If you experience difficulties when attempting to view the above-listed documents simply right-click on the link for the document you wish to view and choose the "Save Target As" or "Save As" option. You'll be prompted for a location to save the report. Save it to a location on your computer and open the document from there.

Get the Adobe® PDF Viewer
 PDF files require the use of the Adobe® Portable Document Format (PDF) viewer available for free from the Adobe web site.

References

  1. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006.
  2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Chronic Myelogenous Leukemia. 2007;1.

See European Summary of Product Characteristics

Glivec® 100 mg film coated tablets (PDF)

Glivec® 400 mg film coated tablets (PDF)

Glivec® 50 mg capsules, hard (PDF)

Glivec® 100 mg capsules, hard (PDF)


About CML Alliance | Treating CML | Targeted Therapies and CML
Monitoring Treatment & Response | CML Resources | CML Events
CML Clinical Trials | Novartis' Commitment to the Global CML Community

Contact | Site Map | Privacy
Use of this website is subject to our Terms of Use

Disclaimer: This site is intended to provide information to healthcare professionals outside the United States. Please note that not all products listed within this site may be available in all countries. Also, prescribing information and indications for products may differ from country to country, so please consult your local Novartis company for local prescribing and any other information you may be interested in.
 
Novartis Oncology
 

© 2010 Novartis AG